Incidence And Management of Complications Associated with Myocardial Infarction

Incidence and Management of Complications Associated With Myocardial Infarction

Authors

  • Muhammad Ahsan Waqar Faculty Of Pharmacy, University of Central Punjab, Lahore, Pakistan
  • Tehseen Riaz Faculty Of Pharmacy, University of Central Punjab, Lahore, Pakistan
  • Imtiaz Majeed Faculty of Pharmacy, University of Central Punjab, Lahore, Pakistan
  • Mustafa Khurram Faculty Of Pharmacy, University of Central Punjab, Lahore, Pakistan
  • Faiza Waseem Lahore College for Women University, Lahore, Pakistan
  • Tooba Mehboob Faculty of Pharmacy, University of Central Punjab, Lahore, Pakistan
  • Naila Tabassam Faculty of Pharmacy, University of Central Punjab, Lahore, Pakistan
  • Rabia Aslam Faculty of Pharmacy, University of Central Punjab, Lahore, Pakistan
  • Irfan Bashir Faculty Of Pharmacy, University of Central Punjab, Lahore, Pakistan

DOI:

https://doi.org/10.54393/pbmj.v5i6.555

Keywords:

Congestive Heart Failure, Myocardial Infarction, Acute Myocardial Dead Tissue, Coronary Artery Disease, Pericarditis, Cardiogenic Shock

Abstract

Coronary heart disease (CHD) is a major cause of morbidity and mortality all around the world. Incidence of the complications of myocardial infarction (MI) had decreased to less than 1% since invention of the percutaneous coronary intervention, although the mortality results from myocardial infarction had decreased in recent years, however the burden of this disease have not ceased. Modern treatment of MI is basically built on any of the clinical evidences that are based on many of the studies that have been studied from previous thirty years. Clinical practice’s evolution had significantly decreased morbidity or mortality linked by this disorder. Severe complications of the myocardial infarction include cardiogenic shock, inferior myocardial infarction, pericarditis and noteworthy right ventricular infarction. These complications are very rare; however, their reputation is neglected for the possible failure to manage early diagnosis and appropriate treatment. Inferior wall myocardial infarction accounts for 40- 50% of all the myocardial infarctions and are mostly seen as having a more promising diagnosis than the anterior wall infarctions. Pericarditis is the common disorder and a complication that arises after the myocardial infarction and has multiple causes. This is present in many secondary care and primary care settings. Frequently pericarditis has been often self-restricted, and the non-steroidal anti-inflammatory agents (NSAIDS) remains treatment of first line in the simple cases. Pharmacological management of complications includes beta blockers, Angiotensin Converting Enzyme Inhibitors, Antiplatelet Agents, and Non-Steroidal Anti-Inflammatory Drugs

References

Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). European heart journal. 2019 Jan 14;40(3):237-69. doi.10.1093/eurheartj/ehy462

Thygesen K, Alpert JS, White HD, Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Journal of the American College of Cardiology. 2007 Nov; 50(22):2173-95. doi.10.1161/CIRCULATIONAHA.107.187397

Frangogiannis N G, Pathophysiology of Myocardial Infarction. Compr Physiol, 2015. 5(4): p. 1841-75. doi.10.1002/cphy.c150006

Saaby L, Poulsen TS, Hosbond S, Larsen TB, Diederichsen AC, Hallas J, Thygesen K, Mickley H. Classification of myocardial infarction: frequency and features of type 2 myocardial infarction. The American journal of medicine. 2013 Sep; 126(9):789-97. doi.10.1016/j.amjmed.2013.02.029

Panju AA, Hemmelgarn BR, Guyatt GH, Simel DL. Is this patient having a myocardial infarction?. Jama. 1998 Oct; 280(14):1256-63. doi.10.1001/jama.280.14.1256

White HD, Chew DP. Acute myocardial infarction. The Lancet. 2008 Aug ;372(9638):570-84. doi.10.1016/S0140-6736(08)61237-4

Herlitz J, Malmberg K, KARLSON BW, RYDÉN L, HJALMARSON Å. Mortality and morbidity during a five‐year follow‐up of diabetics with myocardial infarction. Acta Medica Scandinavica. 1988 Jan 12;224(1):31-8. doi.10.1111/j.0954-6820.1988.tb16735.

Athanasuleas CL, Stanley AW, Buckberg GD, Dor V, DiDonato M, Blackstone EH, et al. Surgical anterior ventricular endocardial restoration (SAVER) in the dilated remodeled ventricle after anterior myocardial infarction. Journal of the American College of Cardiology. 2001 Apr; 37(5):1199-209. doi.10.1016/S0735-1097(00)01089-5

Johansson S, Rosengren A, Young K, Jennings E. Mortality and morbidity trends after the first year in survivors of acute myocardial infarction: a systematic review. BMC Cardiovascular Disorders. 2017 Dec ;17(1):1-8. doi.10.1186/s12872-017-0482-9

AbuRuz ME, Al-Dweik G. Depressive symptoms and complications early after acute myocardial infarction: gender differences. The Open Nursing Journal. 2018;12:205. doi.10.2174/1874434601812010205

Menon V and J S Hochman, Management of cardiogenic shock complicating acute myocardial infarction. Heart. 2002 Nov; 88(5):531-7. doi.10.1136/heart.88.5.531

Anderson J L and D A Morrow, Acute myocardial infarction. New England Journal of Medicine. 2017 May 25;376(21):2053-64. doi.10.1056/NEJMra1606915

Abdallah MH, Arnaout S, Karrowni W, Dakik HA. The management of acute myocardial infarction in developing countries. International journal of cardiology. 2006 Aug 10;111(2):189-94. doi.10.1016/j.ijcard.2005.11.003

Reeder GS. Identification and treatment of complications of myocardial infarction. InMayo Clinic Proceedings. Elsevier. 1995 Sep; 70(9): 880-4). doi.10.1016/S0025-6196(11)63946-3

Lavie C J and B J Gersh. Mechanical and electrical complications of acute myocardial infarction. in Mayo Clinic Proceedings. Elsevier. 1990 May; 65(5):709-730). doi.10.1016/S0025-6196(12)65133-7

Vallabhajosyula S, Subramaniam AV, Murphree Jr DH, Patlolla SH, Ya’Qoub L, Kumar V, et al. Complications from percutaneous-left ventricular assist devices versus intra-aortic balloon pump in acute myocardial infarction-cardiogenic shock. PloS one. 2020 Aug; 15(8):e0238046. doi.10.1371/journal.pone.0238046

Hochman JS, Sleeper LA, Webb JG, Sanborn TA, White HD, Talley JD, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. New England Journal of Medicine. 1999 Aug; 341(9):625-34. doi.10.1056/NEJM199908263410901

Goldberg RJ, Samad NA, Yarzebski J, Gurwitz J, Bigelow C, Gore JM. Temporal trends in cardiogenic shock complicating acute myocardial infarction. New England Journal of Medicine. 1999 Apr; 340(15):1162-8. doi.10.1056/NEJM199904153401504

Tehrani BN, Truesdell AG, Psotka MA, Rosner C, Singh R, Sinha SSet al. A standardized and comprehensive approach to the management of cardiogenic shock. Heart Failure. 2020 Nov; 8(11):879-91. doi.10.1016/j.jchf.2020.09.005

Berger PB, Ryan TJ. Inferior myocardial infarction. High-risk subgroups. Circulation. 1990 Feb; 81(2):401-11. doi.10.1161/01.CIR.81.2.401

Mehta LS, Beckie TM, DeVon HA, Grines CL, Krumholz HM, Johnson MN, Lindley KJ, Vaccarino V, Wang TY, Watson KE, Wenger NK. Acute myocardial infarction in women: a scientific statement from the American Heart Association. Circulation. 2016 Mar 1;133(9):916-47. doi.org/10.1161/CIR.0000000000000351

Kinch JW, Ryan TJ. Right ventricular infarction. New England Journal of Medicine. 1994 Apr 28;330(17):1211-7. doi.10.1056/NEJM199404283301707

Horan LG, Flowers NC. Right ventricular infarction: specific requirements of management. American Family Physician. 1999 Oct; 60(6):1727.

Figueras J, Cortadellas J, Soler-Soler J. Left ventricular free wall rupture: clinical presentation and management. Heart. 2000 May; 83(5):499-504. doi.10.1136/heart.83.5.499

Pappas PJ, Cernaianu AC, Baldino WA, Cilley Jr JH, DelRossi AJ. Ventricular free-wall rupture after myocardial infarction: treatment and outcome. Chest. 1991 Apr; 99(4):892-5. doi.10.1378/chest.99.4.892

Wehrens XH, Doevendans PA. Cardiac rupture complicating myocardial infarction. International journal of cardiology. 2004 Jun; 95(2-3):285-92. doi.10.1016/j.ijcard.2003.06.006

Snyder MJ, Bepko J, White M. Acute pericarditis: diagnosis and management. American family physician. 2014 Apr; 89(7):553-60.

Troughton RW, Asher CR, Klein AL. Pericarditis. The Lancet. 2004 Feb; 363(9410):717-27. doi.10.1016/S0140-6736(04)15648-1

Imazio M, Trinchero R. Triage and management of acute pericarditis. International journal of cardiology. 2007 Jun; 118(3):286-94. doi.10.1016/j.ijcard.2006.07.100

Harari R, Bangalore S. Beta-blockers after acute myocardial infarction: an old drug in urgent need of new evidence!. European Heart Journal. 2020 Oct 1;41(37):3530-2. doi.10.1093/eurheartj/ehaa436

Gong W, Feng S, Wang X, Fan J, Li A, Nie SP. Beta-blockers reduced the risk of cardiac rupture in patients with acute myocardial infarction: A meta-analysis of randomized control trials. International Journal of Cardiology. 2017 Apr; 232:171-5. doi.10.1016/j.ijcard.2017.01.035

Bicket DP. Using ACE inhibitors appropriately. American family physician. 2002 Aug 1;66(3):461.

Pfeffer MA. ACE inhibitors in acute myocardial infarction: patient selection and timing. Circulation. 1998 Jun; 97(22):2192-4. doi.10.1161/01.CIR.97.22.2192

Chassot PG, Delabays A, Spahn DR. Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction. British Journal of Anaesthesia. 2007 Sep; 99(3):316-28. doi.10.1093/bja/aem209

Robless P, Mikhailidis DP, Stansby G. Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease. British Journal of Surgery. 2001 Jun; 88(6):787-800. doi.10.1046/j.0007-1323.2001.01774.x

Fosbøl EL, Gislason GH, Jacobsen S, Folke F, Hansen ML, Schramm TK, et al. Risk of myocardial infarction and death associated with the use of nonsteroidal anti‐inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clinical Pharmacology & Therapeutics. 2009 Feb; 85(2):190-7. doi10.1038/clpt.2008.204

Roumie CL, Choma NN, Kaltenbach L, Mitchel, Jr EF, Arbogast PG, Griffin MR. Non‐aspirin NSAIDs, cyclooxygenase‐2 inhibitors and risk for cardiovascular events–stroke, acute myocardial infarction, and death from coronary heart disease. Pharmacoepidemiology and Drug Safety. 2009 Nov; 18(11):1053-63. doi.10.1002/pds.1820

Aggarwal M, Bozkurt B, Panjrath G, Aggarwal B, Ostfeld RJ, Barnard ND, Gaggin H, Freeman AM, Allen K, Madan S, Massera D. Lifestyle modifications for preventing and treating heart failure. Journal of the American College of Cardiology. 2018 Nov; 72(19):2391-405. doi.10.1016/j.jacc.2018.08.2160

Christman KL, Lee RJ. Biomaterials for the treatment of myocardial infarction. Journal of the American College of Cardiology. 2006 Sep; 48(5):907-13. doi.10.1016/j.jacc.2006.06.005

Molazem Z, Rezaei S, Mohebbi Z, Ostovan MA, Keshavarzi S. Effect of continuous care model on lifestyle of patients with myocardial infarction. ARYA atherosclerosis. 2013 May; 9(3):186.

Downloads

Published

2022-06-30
CITATION
DOI: 10.54393/pbmj.v5i6.555
Published: 2022-06-30

How to Cite

Ahsan Waqar, M. ., Riaz, T., Majeed , I. ., Khurram, M. ., Waseem , F. ., Mehboob, T. . ., Tabassam, N. . ., Aslam, R. ., & Bashir, I. . (2022). Incidence And Management of Complications Associated with Myocardial Infarction: Incidence and Management of Complications Associated With Myocardial Infarction. Pakistan BioMedical Journal, 5(6), 10–16. https://doi.org/10.54393/pbmj.v5i6.555

Issue

Section

Review Article

Plaudit